Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
November 16 2018 - 8:00AM
Neon Therapeutics (Nasdaq: NTGN) has been named one of the top
places to work in Massachusetts by The Boston Globe, an honor
awarded based on employee feedback.
The Top Places to Work awards recognize the most admired
workplaces in the state, as voted on by the employees of those
companies. The annual survey, now in its 11th year, measures
employee opinions about their company’s direction, management,
culture, pay and benefits and engagement with employees, among
other factors.
Neon was ranked first among the small biotech companies surveyed
and sixth overall among Massachusetts companies with fewer than 100
employees.
“We’re especially proud of this honor because the recognition is
based on accolades coming straight from our own team,” said Hugh
O’Dowd, President and Chief Executive Officer of Neon. “I consider
it my most important job as CEO to nurture a culture that lets
every Neon employee do their best work, while building a sense of
common mission. It’s wonderful to have our approach affirmed
through this award.”
The Boston Globe’s rankings are based on confidential surveys
collected by Energage (formerly WorkplaceDynamics), an independent
company specializing in employee engagement and retention. Surveys
were collected this year from more than 82,000 individuals at 318
organizations across the state. The winners share several common
traits, including giving employees a voice in the workplace,
cultivating a culture that makes time for fun and offering strong
benefit packages.
Details about the winning companies were published online
Thursday night and will appear in print in The Boston Globe
Magazine on Nov. 18.
About Neon TherapeuticsNeon
Therapeutics is a clinical-stage immuno-oncology company and a
leader in the field of neoantigen-targeted therapies, dedicated to
transforming the treatment of cancer by directing the immune system
towards neoantigens. Neon is using its neoantigen platform to
develop both vaccine and T cell therapies, including NEO-PV-01, a
clinical stage neoantigen vaccine for the treatment of metastatic
melanoma, non-small cell lung cancer, and bladder cancer;
NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid
tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a
subset of estrogen-receptor-positive breast cancer. For more
information, please
visit www.neontherapeutics.com.
About Boston Globe Media Partners LLCBoston
Globe Media Partners, LLC provides news and information,
entertainment, opinion and analysis through its multimedia
properties. BGMP includes The Boston Globe, BostonGlobe.com,
Boston.com, STAT and Globe Direct.
Media Contact: Stephanie Simon, Ten Bridge
Communications
stephanie@tenbridgecommunications.com
617-581-9333
Investor Contact: Will O’Connor, Stern Investor
Relations will@sternir.com 212-362-1200
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Apr 2023 to Apr 2024